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FUNGAL IPC SYNTHASE ASSAY

alloWs time and conditions for conversion; and (3) identi
fying those potential inhibitors Which actually inhibit con

This application claims bene?t of US. Provisional
Application No. 60/028,079, ?led on Oct. 7, 1996.

version. In one embodiment, the IPC1 gene is overexpressed
so as to provide excess available IPC synthase. In order to
transfect and/or overexpress the IPC1 gene, one in the art
can use conventional methods (ie. J. Sambrook et al.,

BACKGROUND OF THE INVENTION

In

sphingolipid biosynthesis

Chapter 16, Molecular Cloning: A Laboratory Manual, 2d

of fungi,

ed., Cold Spring Harbor Press (1989)) and the materials
disclosed in Example 2.

inositolphosphorylceramide(IPC) synthase is responsible
for transferring inositol phosphate from phosphatidylinositol
to the fungal ceramide to form inositolphosphorylceramide.
The presence of inositolphosphorylceramides have been

10

demonstrated in yeast (S. cerevisiae) and in pathogenic fungi
(C. albicans, Aspergillus fumigatus, H. capsulatum). Lester
& Dickson, 26 Adv. Adv. Lipid Res. 253 (1993). It is also
knoWn that in the model yeast, S. cerevisiae, inositolphos
phosphingolipids are essential for viability. Wells et al., 178
J. Bacteriol. 6223 (1996).

Moreover, although elements of the synthetic pathWay for
sphingolipids in fungi are shared by mammalian sphin
golipid synthesis, the pathWay is divergent at the step after

HoWever, human pathogenic fungal cells may also be used,
including, for example, C. albicans, C. parapsilosis, C.
15

20

candidates for antifungal chemotherapy.
25

1035 (USA. 1979). Regulatory or cis-regulatory sequences

30

SUMMARY OF THE INVENTION

The present invention relates generally to an assay for

inhibitors of IPC synthase. Because this invention makes
35

time and conditions for conversion, and identifying those
potential inhibitors Which actually inhibit conversion.
Preferably, the labeled starting substrates are radiolabeled,

tion. The label can be on either the PI or the ceramide

an effective substrate for IPC synthase. R groups on
40

1,3 diaZole (NBD), 8-methyl-4,4-di?uoro-1,3,5,7
any other small molecule hapten Which an antibody can

recogniZe. Any other ?uorescent moiety can also substitute
45 for NBD or BODIPY.

Radioactive materials, in particular tritium or radioactive
phosphorous, such as 32P or 33P, or carbon, such as 14C, or
?uorescent materials are useful in the present invention.

inhibit IPC synthase by using derivatiZed analogs of the
fungal ceramide as a potential acceptor for the inositol

Radiolabeled and chromogenic substrates are commercially
available from Amersham (2636 South Clearbrook Drive,

phosphate moiety by fungal IPC synthase is also disclosed.

Arlington Heights, 111., 60005 (800-341-7543)) or Dupont
NeW England Nuclear (1007 Market Street, Wilmington,
Del. (800-441-7515)) and Molecular Probes, Inc. (PO. Box
22010, Eugene, Oreg. 97402-0469 (800-438-2209)), respec

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Synthesis of biotinylated fungal ceramide deriva
tive.
55

tively. Substrates can be labeled by any useful means. Those
in the art recogniZe that many ?uorescent markers and
probes can be used, and are aWare of the methods to make
such markers and probes. Typical materials and means for
labelling are described in Martin and Pagano, 159 Anal.

60

Biochem. 101 (1986).
In another embodiment of the invention, phytosphin
gosine (available from Sigma) can be derivatiZed With biotin

biotinylated fungal ceramide.
FIG. 3 DerivatiZed Ceramide Analogues Useful for IPC

Synthase Assays

The presently-disclosed IPC synthase-inhibitor assays
comprise the steps of (1) expression of the IPC1 gene in a

cell; (2) introducing labeled starting substrates for ceramide
conversion as Well as potential inhibitor(s) of such conver
sion to the expressed gene product in an environment Which

N-hexanoyl-sphingosine can be biotin, 4-nitrobenZo-2-oxa

tetramethyl4-bora-3a,4a-diaZa-3-indacene (BODIPY), or

ide. Moreover, a method for identifying compounds Which

DETAILED DESCRIPTION OF THE
INVENTION

capable of being labeled. In particular, C2—C12 ceramides are
preferred for use in this assay. In particular, NBD-C6
substrate. Moreover, N-hexanoyl-sphingosine appears to be

?uorescent or biotinylated derivatives of the fungal ceram

FIG. 2 Schematic SPA assay for IPC synthase using

of the expression vector are preferably those useful for
overexpression as Well. For instance, those that have
galactose-inducible promoters are most preferred.
The starting substrates useful for the present invention can
be any ceramides Which are capable of being converted from
the ceramide to the inositolphophorylceramide and are

ceramide and BODIPY-CS-ceramide are useful in this inven

disclosed herein is more likely.
In one embodiment of the present invention, the assays

comprise expression of the IPC1 gene in a cell, introduction
of labeled starting substrates for ceramide conversion as
Well as potential inhibitor(s) of such conversion to the
expressed gene product in an environment Which alloWs

Novagen. YEp 24 is available from American Tissue Type
Culture Collection (ATCC) under Accession Number 37051.
Yrp7 Was disclosed in Struhi et al., 76 Proc. Nat. Acad. Sci.

disclosed, as is the corresponding amino acid sequence of
the enZyme.

the identi?cation of lifesaving treatments using the assays

Smith, TexasAgric. Exp. Stn. Bull. 1555 (1987). In addition,
preferred vectors include: pYX212; pYX213; pYX012;
pYX013; YEp 24 and Yrp7. These vectors can be commer
cially obtained. The ?rst four in the list can be obtained from

chem. 101 (1986). Thus, inhibitors of IPC synthase are likely

high-throughput screening of potential inhibitors possible,

glabrata, C. tropicalis, C. krusei,A. fumigatus,A. ?avus and
C. neoformans. Moreover, any expression vectors are useful
in the present invention, but vectors useful to overexpress
the gene are preferred. For example, the baculovirus expres
sion system is useful in the present invention. Summers &

formation of ceramide. Martin & Pagano, 159 Anal. Bio

In a copending application, Ser. No. 08/882,767, Dickson,
Lester and Nagiec characteriZed the IPC synthase gene
(IPC1). In that application, the DNA sequence of IPC1 is

Expression of the IPC1 gene can take place in any knoWn
cell line Which is capable of expression of genes. Preferred
cell types include E. coli, S. cerevisiae and S. pombe.

65

by acylation of the free amine With a biotinylated spacer
arm. This procedure provides an analog of the fungal
ceramide With a molecular handle (FIG. 1). The analog can
then be used as an acceptor molecule and conjugated (pre
reaction or post reaction) to streptavidin derivatiZed solid

6,022,684
3

4

substrate such as SPA beads or derivatiZed af?nity chroma

2% Bacto Peptone (Difco), 2% or 4% glucose, 50 mM

tography materials for separation of radio-labeled ceram
ides. Reaction With tritiated phosphatidylinositol as the
donor Would result in scintillation of the SPA by proximity

sodium succinate (pH 5.0), inositol (50 mg/liter), and potas
sium phosphate monobasic (50 mg/ml (Buede et al., 173 J.
Bacterial. 7180 (1991)), or on de?ned medium supple

of the neWly derivatiZed ceramide (FIG. 2). Alternatively,

mented as described (Buede, ibid) and containing, When
necessary, 25 pM (or other indicated concentration of)
phytosphingosine (PHS). PYED buffered to pH 4.1 (PYED
4.1) Was made by mixing 290 ml of autoclaved agar (2% for
plates only), 300 ml of autoclaved yeast extract (1%) plus

labeled streptavidin bound to biotinylated conversion prod
uct can be ?lter-separated. Also, antibodies can be used to

identify hapten-labeled conversion products.
Conditions for conversion can be any of those knoWn in
the art, and can be in vivo or in vitro. One preferred
condition is the use of crude or puri?ed membrane

preparations, incubated according to Becker and Lester, 142

peptone (2%), 100 ml of ?lter steriliZed glycine (0.5 M, pH
3.1), 200 ml of glucose (20%), 10 ml of inositol (0.5%), and
100 ml of potassium phosphate monobasic (0.5%). The pH

J. Bacterial. 747 (1980) and Ko et al., 176 J. Bacterial. 5181

Was 4.1.

10

A diploid version of strain AG27-61 (termed AGD27-61)

(1994).
Prior to the present invention, it Was not knoWn that
inositolphosphotidyl synthase Was an essential enZyme for

15

fungal groWth. That is, although the activity of IPC synthase
Was knoWn, it Was not knoWn that a cell lacking in IPC

synthase activity Would not groW. Therefore, the present
invention provides methods for determining a compound’s
ability to inhibit fungal groWth. In particular, the present

20

invention provides a method to determine the ability of a test

compound to inhibit fungal groWth, comprising the steps of
(1) presenting active inositolphosophotidylceramide syn
thase in a manner such that synthesis of inositolphosphoti

pRS315 (LEU2 CEN4).
25

dylceramide can occur, (2) introducing ceramide and
phospsphotylinositol, said ceramide or phosphatidylinositol

carrying label for identi?cation; (3) subjecting said active
inositolphosophotidylceramide synthase, ceramide and
phosphotylinositol to ordinary conditions necessary for
ceramide conversion to phosphoinositol ceramide; and (4)
identifying those test compounds Which inhibit ceramide
conversion to phosphoinositol ceramide.
Preferred methods to determine a compound’s ability to
inhibit fungal groWth are those Wherein the active inositol
phosophotidylceramide synthase is presented either as a

30

plasmids, 95% of Which carried an insert, Was constructed.
Genomic DNA from derivatives of strain 4R3 resistant to pH
4.1 Was isolated, pooled, and 10 pig Was partially digested
With Sau3AI. DNA fragments of 5 to 10 kb Were isolated
from an agarose gel and ligated With 1 pig of BamHI

DNA Was puri?ed using GeneClean (Bio101, LaJolla,
Calif.), electroporated into E. cali XL1-Blue cells
35

(Stratagene, LaJolla, Calif.), and plasmid DNA Was prepared
from ampicillian-resistant colonies selected on petri plates.
Miscellaneous reagents

Whole cell culture or a membrane preparation from a human

parapsilasis, C. glabrata, C. trapicalis, C. krusei, A.
fumigatus, A. ?avus and C. neafarmans.

Genomic DNA library
A recombinant DNA library containing about 160,000

digested, alkaline phosphatase-treated pRS315. Ligated

For some experiments, the agar in petri plates Was

pathogenic fungal cell culture. HoWever, any fungal cells are
useful in the present invention. The strains that are particu
larly easy to groW and maintain in a laboratory setting are
preferred for these methods. Certain human fungal cells are
listed here to exemplify the human fungal strains Which may
be used in the present inventive method: C. albicans, C.

Was made by transforming haploid cells With a plasmid
(pHO-12 (Russell et al., 6 Mal. Cel. Bia. 4281 (1986))
carrying the HO endonuclease gene, responsible for sWitch
ing of the mating type. Leu+ transformants Were streaked
onto PYED plates and colonies containing MATa/MATalpha
diploid cells Were identi?ed by their large, ellipsoidal mor
phology. Diploids Were screened on de?ned medium lacking
leucine for Leu- cells, indicating loss of the plasmid carrying
the HO gene, and tested for transformation ef?ciency using

40

replaced With agarose (Fisher, BP160-500). pIPC1 is a
plasmid isolated from the recombinant DNA library
described above in Which the 4307 base pair insert corre
sponds to S. cerevisiae Chromosome XI betWeen coordi
nates 432,813 and 437,119 as described in the Saccharamy
ces cerevisiae genome database at Stanford University

45

(http://genome.WWW.stanford.edu).
Isolation of strain AG27-61

Strain 7R6 Was groWn overnight in PYED plus 25 pM
PHS (referred to here as the medium) and then mutageniZed
With ethylmethanesulfonate to give 20% killing as described
in Pinto et al., 174 J. Bacterial. 2565 (1992). MutageniZed

EXAMPLES

Example 1
IPC1 Complementation of IPC Synthase Defect by

cells Were diluted to an absorbance at 600 nm (A600) of 0.4

IPC1
A. Identi?cation of IPC1 defective cell.

With medium, incubated With shaking at 30° C. for 7 h,

Strains, plasmids, and culture conditions: S. cerevisiae
strains are: 7R6 (MATa ura3-52 leu2-3,112 lcb1::URA3
SLC1-1 ade1) (Dickson et al., 10 Mal. Cell. Bia. 2176
(1990)) Which Was derived from Wild type strain SJ21R

resuspended in 2 ml of medium and sonicated using a

during Which time the A600 increased to 2.5, centrifuged,
55

(MATa ura3-52 leu2-3,112 ade1); YPH250 (MATa ura3-52

lys2-801mb” ade2-1010Chre trp-A1 his3-A200 leu2-A1)
(available from the ATCC, and useful to make the other

60

strains, by common means); AG27-61 (MATa ura3-52 leu2
3,112 lcb1::URA3 SLC1-1 ade1 lys2-801amber ipc1-1) Was
derived from 7R6 by the procedure described beloW.
pRS315 is a standard yeast vector and described in Sikorski

et al., 122 Genetics 19 (1989).
Yeast Were groWn on modi?ed PYED (bufferred to pH

5.0, PYED-5.0) Which contained 1% yeast extract (Difco),

65

microtip (Heat Systems-Ultrasonic) for 2 min to disrupt
clumped cells. One ml of cells Was layered on 4 ml of 30%
sodium diatriaZoate (see Pinto et al., 174 J. Bacterial. 2565
(1992)) and centrifuged at 10° C. in a Sorvall RT6000B
centrifuge for 4 min at 2000 rpm. Most cells Were at the
interface but a faint pellet of dense cells Was present at the
bottom of the tube. The liquid Was aspirated and the cell

pellet Was carefully resuspended in 0.5 ml of medium to
avoid mixing With cells stuck to the side of the tube.
Resuspended pellets from tWo tubes Were mixed and
re-centrifuged on 30% sodium diatriaZoate. The cell pellet
Was resuspended in medium and about 500 cells Were spread
on PYED plates containing 25 pM PHS. TWo days later only

6,022,684
5

6

about 15 colonies per plate Were visible, suggesting only 3%

phosphatidylinositol, membranes, and Water to 200 pl total
volume. Typically 75—300 pg of membrane protein Were
added per reaction. The membrane proteins Were prepared
according to Pinto et al., 174 J. Bacteriol. 2575 (1992),
except that the buffer contained 1 pig/ml of leupeptin,
pepstatin and aprotinin and, in addition, the cells Were
shaken With glass beads for 6 thirty second intervals With a
2 minute period for cooling on ice betWeen the intervals. The

of the dense cells Were viable.
Putative mutants Were screened to differentiate those

speci?cally defective in sphingolipid synthesis from those
defective in other lipid biosynthetic pathWays Which might
also affect cell density. The screen Was based upon the
observation that strain 7R6 cannot groW at loW pH When it

lacks sphingolipids (no PHS present in the medium) but can
groW When alloWed to make sphingolipids (PHS present in
the medium, Patton et al., 1992, J. Bacteriol.

reaction mixture Was sonicated for 1 min in an ultrasonic

Water bath before addition of membranes and then incubated
for 15 or 30 min at 30° C. With gentle shaking. The reaction

174:7180—7184). Thus, about one hundred mutants unable
to groW on PYED plates at pH 4.1 either in the presence of

Was stopped by addition of 2.8 ml of 96.43% methanol (?nal
methanol concentration of 90%). After standing for 10 min

25 mM PHS Were identi?ed.
Mutant strains Were examined further for a defect speci?c

the mixture Was centrifuged at room temperature. TWo ml of
the supernatant ?uid Were mixed With 4 ml of tert-butyl

to sphingolipid synthesis relative to glycerophospholipid

synthesis by looking for decreased incorporation of [3H]
inositol-containing sphingolipids relative to phosphatidyli
nositol (ZWeerink et al. 1992 J. Biol. Chem.

methyl ether (Sigma-Aldrich, HPLC grade), then With 2 ml
of Water, folloWed by vortexing, and centrifugation. The

267:25032—25038). By this assay, strain AG27-61 appeared
to be speci?cally defective in sphingolipid synthesis.

extracted tWice more With 4 ml portions of mock upper

[3H]N-acetylsphinganine labeling of sphingolipids in

loWer phase containing the product of the reaction Was

phase, prepared by mixing 2 parts of reaction mixture
20

v1vo

parts of Water. The volume of the loWer phase Was measured,

Was measured as folloWs. PYED medium Was added to tubes

and 1 ml Was added to 4 ml of scintillation cocktail and

containing solid [3H]N-acetylsphinganine (860 cpm/pmole)
and the mixture Was dissolved by treatment for ?ve minutes
in an ultrasonic Water bath. Log phase cells, groWn in PYED

(lacking N-acetylsphinganine, phosphatidylinositol, and
membranes) With 4 parts of tert- butyl methyl ether plus 2

Cellular conversion of [3H]N-acetylsphinganine to IPC

counted in a liquid scintillation spectrometer. The cocktail
25

medium, Were centrifuged, suspended in fresh medium and
added to the radiolabeled medium to give a ?nal cell density

contained 4 gm/l of 2-(4‘-t-butylphenyl)-5-(4‘-biphenylyl)
1,3,4-oxadiaZole, 3 gm/l of 2-(4‘-biphenylyl)-6
phenylbenZoxaZole, 33.3% Triton X-100, and 66.7% tolu
ene. IPC synthase activity Was expressed as pmoles of IPC

of 1.5 A600 units/ml. The ?nal concentration of
N-acetylsphinganine Was 5.0 pM. At the indicated times, 1
ml samples Were removed, quenched With trichloroacetic
acid, and processed as in the inositol-labeling procedure.
Qualitative analysis of 25 pl samples Was carried out on
20 cm Whatman HP-K plates developed With
chloroform:methanol:4.2N NH4OH (9:7:2). Each lane con
tained 2 nmoles of IPC-3 (IPC With a monohydroxylated

made/min/mg protein.
Alternative in vitro assay for IPC Synthase—the ?lter

binding assay
This assay is based on the difference in charge betWeen

the substrate for IPC synthase, N-acetylsphinganine

(uncharged) and the product, IPC (negatively charged). Test
reactions Were performed to determine if the charge differ
ence betWeen substrate and product could be the basis for an

fatty acid, 2) internal standard. Radioactivity Was measured
by using a BioScan apparatus and the plates Were sprayed

assay procedure. The test reactions shoWed that N-acetyl

With a 10% solution of CuSO4.5H2O in 8% H3PO4 and

[3H]sphinganine-P-Inositol (IPC) binds tightly to the fol

charred at 160° C. to locate the IPC-3 standard.

loWing anion-exchange ?lter papers (all made by Whatman):
AE30, aminoethylcellulose; AE81, aminoethylcellulose;

Quanti?cation of radioactive products Was achieved by
ascending chromatography of 5 pl samples on Whatman
SG-81 paper Washed With ethylenediamine tetraacetate (see
Steiner and Lester, 260 BBA 222 (1972)) and developed With
chloroform methanol:4.2N NH4OH (9:7:2). The lanes Were

and DE20, diethylaminoethylcellulose. An enZyme reaction
mixture Was prepared in a volume of 100 pl to give these

cut into one cm Zones and counted in a liquid scintillation
45

spectrometer.

?nal concentrations: 100 mM TRICINE (pH 8.1), 0.02%
Tergitol, 1 mM phosphatidylinositol, 100 pg of membrane
protein, prepared as for the in vitro assay of IPC synthase
described above. The reaction also contained either N-acetyl

In vitro assay of IPC synthase
The inventors elected to develop a less time consuming

[3H]sphinganine (152550 cpm, 67 pmoles) or N-acetyl-[3H]
sphinganine-P-Inositol (251700 cpm, 110 pmoles). The

assay for measuring IPC synthase activity than the published

reaction Was immediately quenched by adding 9 volumes of
95% ethanol. Samples (20 pl) Were applied to 2.3 cm

assay Which uses chromatography to separate radiolabeled

substrate from product, IPC (Becker and Lester, 142 J.

diameter DE20 and DE81 ?lters and air dried. The ?lters

Bacteriol. 474 (1980), K0 et. al., 176 J. Bacteriol. 5181

Were Washed With 95% ethanol and radioactivity Was mea

(1994)). The improved procedure separates the substrate and

sured by counting in a liquid scintillation spectrometer. The

product by differential solvent extraction. A substrate mix

results are shoWn beloW:

N-acetyl-[3H]sphinganine-P-Inositol
N—acetyl[3H]sphinganine

DE20

DE81

(% Original Radioactivity on Discs)

(% Original Radioactivity on Discs)

109
2.6

90.4
1.4

ture containing 50,000 cpm of [3H]N-acetylsphinganine and
20 nmoles of N-acetylsphinganine, Was added to a plastic

suspended in 50 pl of 0.2 M potassium phosphate, pH 7.0,

These data demonstrate that the substrate N-acetyl[3H]
sphinganine barely binds to the ?lter paper under the solvent

20 pl of 20 mM CHAPS (Sigma), 40 pl of 5 mM aqueous

conditions used, While the charged product N-acetyl-[3H]

tube, and dried using a stream of N2. The dry mix Was

65
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sphinganine-P-Inositol binds very Well. These results pro
vide a simple and fast assay for IPC synthase enzyme

Whereas the parental strain 7R6 is able to groW because it

activity.
Preparation of [4,5-3H]N-Acetylsphinganine

sis then AGD27-61 cells transformed With the plasmid
should behave like 7R6 cells and groW on PYED-4.1 plates
containing 25 pM PHS. (According to Patton et al., 174 J.
Bacteriol. 7180 (1992). This expectation Was ful?lled by all
30 AGD27-61 transformants tested While cells transformed
With the vector did not groW. These data indicate that pIPC1
carries a gene that complements the IPC synthase defect in
AGD27-61 cells and restores sphingolipid synthesis When

makes sphingolipids. If pIPC1 restores sphingolipid synthe

N-acetylsphingosine Matreya, Inc.) Was reduced in etha
nol With Tritium gas (American Radiochemicals, Inc.) in the
presence of Adams catalyst. The sample Was dried, dis
solved in 0.2 ml chloroform, and applied to a 05x50 cm

column of Adsorbosil (100/200 mesh) preWashed With chlo
roformzmethanol (1:1) and equilibrated With chloroform.

10

The elution schedule Was: 14 ml of chloroform folloWed by

cells are fed PHS.

To identify the genomic region carried in pIPC1, the

chloroform-methanol (97:3), collecting 7 ml fractions. Frac
tions 11—16 Were pooled, dried, dissolved in methanol,

applied to silica gel thin layer plates (Whatman LK5) and
developed With chloroformzmethanol (95:5). The appropri

nucleotide sequence at the ends of the genomic insert Was
determined and used to search the Saccharomyces genome
15

database (http://genome.WWW.stanford.edu). This search

ate Zone, located by autoradiography, Was scraped and

identi?ed a region of 4307 bases located on Chromosome XI

transferred to a syringe ?tted With a Te?on ?lter (Acro

betWeen coordinates 432,813 and 437,119. There is only one

LC3S, 0.45”, Gelman Sciences, Inc,). The [3H]N

complete open-reading frame (YKL004W, AUR1) in this

acetylsphinganine Was eluted With 8 ml of methanol. The

interval, Which is shoWn in SEQ ID No:1.
As shoWn in the folloWing examples, AUR1 encodes IPC
synthase. The gene has been renamed IPC1.
C. The IPC1 gene restores IPC synthase activity to AG27-61
cells.
Membranes Were prepared from the control parental strain
7R6 and from AG27-61 cells transformed With pIC1 or With
a control vector (pRS315) and assayed for IPC synthase
activity. Membranes from AG27-61 cells transformed With
pIPC1 contained more IPC synthase activity than did the

thin layer chromatography step Was repeated. The ?nal

20

product, With the same mobility as authentic

N-acetylsphinganine prepared according to a published pro
cedure (Gaver and SWeeley, 88 J. Am. Chem. Soc. 3643

(1966)), had a speci?c activity of 1.5><107 dpm/nmole.
Miscellaneous procedures

25

Yeast Were transformed using LiOAc-treated cells (GietZ
et. al., 8 Nucleic. Acids. Res. 1425 (1992)). Protein concen
tration Was determined With the Bradford reagent using
bovine serum albumin as standard (BioRad Inc.).
B. Isolation of the IPC1 gene.
A gene that complemented the defect in AG27-61 could

membranes from the 7R6 positive control cells (Table 1).
30

Membranes from AG27-61 cells transformed With pRS315

contained barely detectable enZyme activity (Table 1).

not be isolated directly from the haploid because the strain
transformed at too loW a frequency, about one transformant

TABLE 1

per microgram of plasmid DNA. Since diploid yeast strains
are generally more vigorous, a diploid version of AG27-61
Was examined and found to be transformed at a high enough

35

frequency to alloW screening of a recombinant DNA library.
One diploid strain, designated AGD27-61, Was transformed
With a recombinant DNA library carried in pRS315. Apool
of about 3000 Leu+ transformants Was treated With 10 pM

40

phytosphingosine (PHS) to enrich for the desired transfor

Strains

IPC Synthase activity (pMoles/min/mg protein)

7R6

103 r 19

AG27-61/pIPC1
AG27-61/pRS315

159 r 9
0.2 r 0.07

Restoration of IPC synthase activity by pIPC1 Was also
examined by using an in vivo labeling procedure in Which

mant. The rationale for this treatment Was based upon the

cells Were incubated With a membrane-permeable ceramide,

observation that AG27-61 cells die rapidly When treated
With 10 pM PHS at a loW cell density in de?ned medium.
FolloWing PHS treatment, transformants Were spread at
various densities on petri dishes containing de?ned medium
lacking leucine, agarose in place of agar, and 10 or 20 pM
PHS. Agarose Was used in place of agar to enhance the

[3H]N-acetylsphinganine, to radiolabel sphingolipids, spe
ci?cally IPC. The concentration of radiolabeled IPC
45 increased in an almost linear fashion over the 3 hour course

of the experiment in A27-61 cells transformed With pIPC1
and, thus, these cells behave like the positive control cells,
7R6 transformed With pRS315, Whereas AG27-61 cells
transformed With pRS315 shoWed no synthesis of radiola

effective concentration of PHS Which appears to bind to

components in regular bacterial agar. PHS-resistant colonies
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Were obtained from cells transformed With the genomic
library but not from an equal number of cells transformed
With the vector.

FIG. 2 demonstrate that pIPC1 carries a gene that restores

IPC synthase activity to AG27-61 cells.

Example 2

Plasmid DNA from four PHS-resistant colonies Was res

cued in Escherichia coli. The four plasmids, termed pIPC1,
gave the same EcoRI restriction fragment pattern, indicating
that they carry the same genomic DNA region. Each of the
four pIPC1 DNA samples gave transformants When retrans
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albicans

et al., 176 J. Bacteriol. 5181 (1994)., except that membranes
60

AGD27-61 transformed With the vector pRS315 gave no
PHS-resistant transformants at the higher PHS concentra

(Amersham) in a reaction volume at 100 microliters at 30

carried on pIPC1.

loid or diploid, prevents them from groWing on PYED plates

having a pH of 4.1 (PYED-4. 1) When PHS is present

from C. albicans at a concentration of 25 micrograms per
reaction, and exogenous C6 ceramide, at a concentration of

0.2 millimolar, With tritiated phosphatidylinositol

tion. These data shoW that the PHS-resistance phenotype is

The sphingolipid synthesis defect in AG27-61 cells, hap

Initial Results from IPC Synthase Assay from C.

Using protocol similar to the procedure described by K0

formed into AGD27-61 and selected on de?ned medium

lacking leucine and containing 1 or 12 pM PHS Whereas

beled product (FIG. 2). The data presented in Table 1 and
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degrees centigrade at 2 hours the folloWing results Were
obtained: Reaction conditions indicated incorporation of
tritiated phosphoinositol into the C6 ceramide and Was
inhibited by addition of R106-1 (also knoWn as Aureobasi

6,022,684
10
CHAPS, 560 pl deioniZed Water, 80 pl 0.5 M KPi buffer, pH

din A) at 20 micrograms per ml. (R106-1 is disclosed by
Takesako et al. 44(9) J. Antibiot. 919 (1991) and Ikai et al.,
44 (9) J. Antibiot. 925 (1991).
Example 3
IPC Synthase Assay: FLUOR Method

7.0 and sonicated for 5 minutes. This Was considered “2x
master mix”.

Membrane stock Was thaWed and diluted to 1.8 mg/ml in

Strains YPH1Wt and SH2-3B AUR1R Were inoculated

into YEPD (5 ml) supplemented With 20 pig/ml inositol and
groWn overnight at 30° C. With shaking. Precultures Were

then inoculated into 250 ml of YEPD+20 pig/ml myo-inositol

10

and groWn overnight at 30° C. With shaking. Cells Were

harvested at betWeen 5><107 cells/ml by centrifugation at
2000><g for 10 minutes. Cells Were resuspended in ice-old 50

mM potassium phosphate buffer, pH 7.0 and transferred to

0.05 M KPi buffer, pH 7.0 and kept on ice.
Reaction Conditions
50 pl of 2x master mix Was aliquoted into screW-cap
microfuge tubes and kept at room temperature. 20 pl of 0.05
M KPi buffer pH 7.0 Was added to each sample, folloWed by
5 pl of test compound or extract in 50% (max) organic
co-solvent. The reaction Was initiated by adding 25 pl of
membrane stock to each reaction vessel, mixing, and incu
bating at room temperature for 15 minutes.
Reactions Were terminated by addition of 900 pl of ice

a 50 ml conical tube. The cells Were then Washed tWice With 15 cold absolute methanol. Samples Were then stored at —20° C.
for at least one hour and then centrifuged at 14,000><g at 4°
The cells Were then resuspended as a slurry in 5—10 ml of
C. for 30 minutes. Fluorescence levels Were measured using
cold 50 mM potassium phosphate, pH 7.0, containing 5 mM
the FLUOR method: RP-HPLC:

ice-cold 50 mM photassium phosphate buffer, pH 7.0.

DTT, 1 pig/ml aprotinin, 0.6 pMleupeptin, 1 mM PMSF and
1 pig/ml peptatin A. The buffer With protease inhibitors Was
made fresh just before use and kept cold.
Next, the slurry Was tranferred to 2 ml tubes (Mini-beater

20

FLUOR Method

tubes) and the cells Were pelleted by centrifugation at
2000><g for ?ve minutes at 4° C. This Was repeated until the
packed cell volume Was 50% of the tube volume or greater,
but less than 75%. The remaining supernatant Was removed
and 500 pmglass beads Were added to the top of the tube. To
this Was added 50 mM potassium phosphate, DTT and
protease inhibitors to ?ll up the remaining volume. The vial

Column: Beckman Ultrasphere-ODS
5 urn, 150 x 4 mm

25

Buffer: 87% MeOH/13% 50 mM TEAP pH 5.85
FloW: 1 ml/min

Temp: Room temp
Detector: Beckman Model 157 Fluorescence detector
excitation: 475 nm
emmission: 520 nm

Was sealed With a screW cap.

Analysis time: 12 min.

The cells Were then disrupted in a Mini-bead beater for 30

30

seconds, ?ve times With 2—5 intervals on ice for cooling. The

Procedure
100 pl of reaction supernatant Was placed in an HPLC
microvial. 25 pl of reaction mixture Was injected and the

disrupted cell paste Was separated from the glass beads by
?ltering through glass Wool into a chilled centrifuge tube on
ice. The beads are rinsed With cold buffer Which Was pooled

With the original ?ltrate. The centrifuge tube Was then

35

centrifuged at 2000><g for ten minutes at 4° C. to remove cell
debris.
The supernatant Was transferred to an ultracentrifuge tube

and the membranes Were pelleted by centrifugation at 100,
000><g for sixty minutes at 4° C. The supernatant Was

40

discarded and the pellet resuspended in cold buffer, DTT and
protease inhibitors and reharvested by ultracentrifugation a
second time. The ?nal membrane pellet Was resuspended in
a minimal volume of cold buffer, DTT and protease inhibi
tors and then transferred to a chilled dounce homogeniZer.
The membranes Were homogeniZed With 5—6 strokes of a
pestle on ice. The membranes Were then diluted With 1/3

chromatogram developed isocratically. Calculation Was per
formed as % product formed:

Under the stated conditions, depending on the speci?c
activity of the membrane preparation, 10—15% product Was
formed. The reaction pro?le in this range of product forma
tion is in the linear portion of the reaction curve.

Example 4

45

Biotinylated Ceramide Reaction
2>< master mix Was prepared using the folloWing recipe
and With the folloWing consituents:

volume of glycerol (?nal 33%) glycerol) and mixed Well by
inversion. Aliquots Were then placed in screW cap microfuge
tuges and froZen on dry ice/ethanol and stored at —80° C.

2>< master mix Was prepared using the folloWing recipe
and With the folloWing consituents, to give as ?nal concen
trations in the reaction:

Biotin—C6—ceramide
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2 ,uM

phosphatidylinositol (Sigma — soybean)

0.05 mM

CHAPS

2 mM

potassium phosphate buffer, pH 7.0

50 mM

Organic Co-solvent

up to 2.5%

NBD—C6—ceramide (Molecular Probes)

5 ,uM

(non-speci?c) protein concentration

0.45 mg/ml

phosphatidylinositol (Sigma — soybean)

1 mM

Final Volume

50 #1

CHAPS

2 mM

potassium phosphate buffer, pH 7.0

50 mM

Organic Co-solvent

up to 2.5%

(non-speci?c) protein concentration

0.45 mg/ml

Final Volume

100 #1

60

To the above solution, 8.4 pl Biotin-C?-ceramide (0.1
mg/ml in MeOH) and 35 pl phosphatidylinositol (1 mg/ml in
CHCl3) and tritiated phosphatyldylinositol (10 Ci/mmol)
Were added, and the product dried in vacuo.

To the above solution, 46 pl NBD-C?-ceramide (0.1

mg/ml in MeOH) and 142 pl phosphatidylinositol (10 mg/ml
in CHCl3) Were added, and the product dried in vacuo.
The dried product Was then redissolved by adding the

folloWing ingredients in the folloWing order: 160 pl 20 mM
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The dried product Was then redissolved by adding the
folloWing ingredients in the folloWing order: 80 pl 20 mM
CHAPS, 280 pl deioniZed Water, 40 pl 0.5 M KPi buffer, pH
7.0 and sonicated for 5 minutes. This Was considered “2x
master mix”.

6,022,684
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12

Membrane stock Was thawed and diluted to 1.8 mg/ml in

0.05 M KPi buffer, pH 7.0 and kept on ice.
Reaction Conditions
25 pl of 2x master mix Was aliquoted into screW-cap
microfuge tubes and kept at room temperature. 10 pl of 0.05
M KPi buffer pH 7.0 Was added to each sample, followed by
2.5 pl of test compound or extract in 50% (max) organic
co-solvent. The reaction Was initiated by adding 12.5 pl of

membrane stock to each reaction vessel, mixing, and incu
bating at room temperature for 2 hours.
Reactions Were terminated by addition of a suspension of

streptavidin-conjugated scintillation proximity beads (4 mg
in 200 pl) and the mixture incubated With the beads With
shaking for one hour at room temperature.
The radioactivity of the product Was counted in a scin
tillation counter or in a microplate scintillation counter such
as a Top-Count (Packard).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 1

(2)

INFORMATION FOR SEQ ID NO:1 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4307 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 :
GATCTTTCAT CATTGTGACT GCCTAAAATA TCTTTCAAAA TTTCAGGAAT TTCACCGCCC

60

TTCGATGGAA CGATATAAAA ATCCTTCTCG TATCTAGTTT TTGGCTTTAT ACCTGCAATG

120

CGACCTTTGT TTTCCAGGGA GTCTACAACG TCGGCAAAAG TTGTCTTACT TTCACTATCA

180

TTCGAAGGAA ATAATTGGTA TACTAATATA GCTCTAGAGC AAGAAATTTC CTTAAGATAT

240

GGTGCAGCAG TGGTTGTAGG TAAGCGCCCT TCTACATACA GTTTTCCGTC ACCAATGGCT

300

TCCTTGAAAA TATCCCGTCT TAACTTTTGT GAAGCCCCAA TGTAGTTTAG GTAACCTGTA

360

AACTCAAGTC CTAAGCCGGG ATACAAAAAT GCGCAGTTTA AAGATTCTTC GTTGATTATT

420

GTACTTGGGC TGGGTTCTTT CGAAATGGCA TGAGTCTGTT CTATTTTACT CTTATCGCTG

480

TCGATACTGT CAATGTTGTG TAATCTTATG CTGTCTTTTG AGTACAAAAT ATCCTCTTGA

540

GGTTCAGCGA TATCTTCGAT CAGCTCATCA CCCTTGTGGG TCTTAACGTA CATGGGTTTG

600

TCAGGTACCT CCACGATAAA ATTTTCTAAG ATAATCTTAT CCCTTTTCTC TTTAAATTCT

660

TGTAAGTCAG GATTTGCGAG TTCAGATGCG TTCATGTTCA CCAGTTTATT TAAAGGCAAT

720

TTGCCCTCGA CAACGTGTGC CTTCAGTTCC AAATTTTTTT TATCCTTTAA ATTAGAGTAT

780

AACGACCTCA CTTTCTCTGT GTATATCTTG TCCAAAGTAC CAAACTCGAC GTTAAGGCAA

840

GCTTTGTAAA GTTCTTCTTC CAGATTGTGC GCAAACTCTT GCGATATCGA TATAACGTCT

900

TTCCCATCAG GAAGCTCATA AAGTTTTGCC TCAATTGTTT CGGGAACGAT GAATTTGCTA

960

AATAAGGTAG AGAACATTTT TTCTGCATTA TACCTCAGTT TGTGTTCTTT TTCGCTTTCA

1020

AAATCTTTCC TAGTAGGCAT TTCGTTTTCG GCAGTATCAG ACTTGGCGGC ATCAATGCTT

1080

TTATTCCTTT TTTTTGACCC ATTGGATTTC TTCACCTGTT TGGATTTGAT ATGAATTCCT

1140

TTGGCACTAT CGGGGCTCCT TTTTCGTTTC CTAGGGCTTT CCTCATCAAG AAAGACATCT

1200

GCATCATTGT CATCATGGTC ATTTACGGGC TTGTAAACAT CATCATGGTA ATCTTCATCC

1260

TCTGAAACCT CTGCCTCCTT TGACGTTTCC AAATGTGCAT ACAATGATGG GTCGCACAAT

1320

6,022,684
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14
-continued

TCACAGTAGT ACTTAGAATC TTCACTCATT AGCCCATCTA TGGTGTCTTT ACCATCAGTC

1380

ATACATTTAA TATGCTGCCA AGTGTCACAG CCATCGCACT GTACCATGTC GCCATGCGAA

1440

TATTCTGCAG CATCGTAGTT TTCATTGTTC GCCCCACACA GACATCTAAC ATAGCCCTCA

1500

TCCGCTTCGT CTACTTCGTC TGTTCTTACA TTTTCAGTAT CTTTCCTTGG CTCCTGAGAA

1560

GAATCAGACT TCTTATTCTT CTCTATGGCT GAATCAACTT TCTTTTTAGT TCTTTTTTTC

1620

TTTGGTGCTT CAGTCTCCTC CTGTAACAAA TACTCAATAT ATTTATTCTG ACCCTTATTA

1680

GATCTTGAAG AAGTACGGAC AGACATAATA AATTTAAACT AAATAAAAGC TAAAAGTAAA

1740

AGAGAACCTA GGATAATCGA TAGCTCCCTG TGTATAGAAC AAGTCAAAAT ACTAAGATCT

1800

CGTCAACCTA TCCTCTTTCA TTGCAAGCCT TTTGGCCAAA CTGCAGTCTG GGCATCCCTT

1860

TGCATGTCTT GTGAAATAGT ATCCATCTCT CCCCAGCTCC CAGAAATGAT ATGAAAAGTT

1920

ATTCGTGAAG AGTGATCCTA AAACTGAAAA AAGGAAAAAA CAAAAATGAG CTAAAAAAAC

1980

CACAACAAAA GAATATCAAC TTCATTGCTT GGCGGGTCAT CGCTTTTTTA TTTCTTTCTG

2040

TCAAAGAATA ATAAAGTGCC CATCAGTGTT CATATTTGTT ACAAAGTGGT TTTCTGATTT

2100

GGTACTACTG CAGAGGCGTA TTTTTTGCTT CAGTTACCAT AGCGTAAGAA CACTAGCGAC

2160

TTTTGTTCGT GAACCAACAG AGTAGGATTT CTACTGCTAC ATCTCTTAGG TAGTTGGTTA

2220

GTCCGATCGC TCACTTTTGG TTGTTGTTAA GTACTTCATA AGTTTATCCT TTTCCTTTTT

2280

CACACTGAGC TACTTTGGGT ATAGCTTTTG GCCCAAGGAT CTTTGAATTT TCTCCAAAAG

2340

TACTTTATTT TATATCCTAC AGGTTGCGGT TTTCATATTT TAAAAAGCTT TTAATCATTC

2400

CTTTGCGTAT GGCAAACCCT TTTTCGAGAT GGTTTCTATC AGAGAGACCT CCAAACTGCC

2460

ATGTAGCCGA TTTAGAAACA AGTTTAGATC CCCATCAAAC GTTGTTGAAG GTGCAAAAAT

2520

ACAAACCCGC TTTAAGCGAC TGGGTGCATT ACATCTTCTT GGGATCCATC ATGCTGTTTG

2580

TGTTCATTAC TAATCCCGCA CCTTGGATCT TCAAGATCCT TTTTTATTGT TTCTTGGGCA

2640

CTTTATTCAT CATTCCAGCT ACGTCACAGT TTTTCTTCAA TGCCTTGCCC ATCCTAACAT

2700

GGGTGGCGCT GTATTTCACT TCATCGTACT TTCCAGATGA CCGCAGGCCT CCTATTACTG

2760

TCAAAGTGTT ACCAGCGGTG GAAACAATTT TATACGGCGA CAATTTAAGT GATATTCTTG

2820

CAACATCGAC GAATTCCTTT TTGGACATTT TAGCATGGTT ACCGTACGGA CTATTTCATT

2880

TTGGGGCCCC ATTTGTCGTT GCTGCCATCT TATTCGTATT TGGTCCACCA ACTGTTTTGC

2940

AAGGTTATGC TTTTGCATTT GGTTATATGA ACCTGTTTGG TGTTATCATG CAAAATGTCT

3000

TTCCAGCCGC TCCCCCATGG TATAAAATTC TCTATGGATT GCAATCAGCC AACTATGATA

3060

TGCATGGCTC GCCTGGTGGA TTAGCTAGAA TTGATAAGCT ACTCGGTATT AATATGTATA

3120

CTACAGCTTT TTCAAATTCC TCCGTCATTT TCGGTGCTTT TCCTTCACTG CATTCCGGGT

3180

GTGCTACTAT GGAAGCCCTG TTTTTCTGTT ATTGTTTTCC AAAATTGAAG CCCTTGTTTA

3240

TTGCTTATGT TTGCTGGTTA TGGTGGTCAA CTATGTATCT GACACACCAT TATTTTGTAG

3300

ACCTTATGGC AGGTTCTGTG CTGTCATACG TTATTTTCCA GTACACAAAG TACACACATT

3360

TACCAATTGT AGATACATCT CTTTTTTGCA GATGGTCATA CACTTCAATT GAGAAATACG

3420

ATATATCAAA GAGTGATCCA TTGGCTGCAG ATTCAAACGA TATCGAAAGT GTCCCTTTGT

3480

CCAACTTGGA ACTTGACTTT GATCTTAATA TGACTGATGA ACCCAGTGTA AGCCCTTCGT

3540

TATTTGATGG ATCTACTTCT GTTTCTCGTT CGTCCGCCAC GTCTATAACG TCACTAGGTG

3600

TAAAGAGGGC TTAATGAGTA TTTTATCTGC AATTACGGAT ACGGTTGGTC TTATGTAGAT

3660

ACATATAAAT ATATATCTTT TTCTTTCTTT TTCTTAGTCA GGATTGTCGT TTAGCATAAT

3720

6,022,684
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16
-continued

ATACATGTAG TTTATTTAAT CACATACCAC TGATTATCTT TAGAATTTTA TAAATTTTTG

3780

AAATAAATGG GTGGCTTTTA ATGGTGTCTA TGTTAAGTGA GGCTTTTAGA ATGCTCTTCC

3840

TGCTTTGTTT ATTATATGTG TATGAAAGAT ATGTATGTAT TTACATGTGT TTGTAGCGTC

3900

CCCAGTCAAA ACCTGTGCGC TATACCTAAA TGGATTGATA ATCTTCATTC ACTAATTCTA

3960

AAATAGACTT CTTCCCCAAA GAACGGTGTA ACGATGAGGC TCTATCCAGC TGCTTATCTA

4020

AATCAACTTT AACGATGGAT GATCTTATGA CACGGGGATC TTTCTTTAAA GTTCTTAGAA

4080

TTTCAGACTG TACCGCAGCT GATGAATCAA ACAGCATTAA AAAGTGATAT GCTCGAAAAT

4140

GTTTTTCCTG GTCTTTCTTC ATTATTTTAG GAAGATACCT TATGCCCATG GGTACAATGT

4200

CCCTCACCAC ACCTCTGTTT TGAATAATCA GTTTCCCGAT TGTGGAAGAC AATTCTTTTG

4260

CTTCCAACTT TGGCGCATTG GAGTTGGTTA TGCGAACAAG TCCGATC

4307

conjugating said biotinylated ceramide to streptavidin

What is claimed is:
1. A method to determine the ability of a test compound

to inhibit inositolphosphorylceramide (IPC) synthase, com
prising:

recombinantly expressing the Saccharomyces IPC1 gene
in a plurality of cells transformed to express said gene,

said cells being in homogeneous culture and located in
a container useful for addition of liquids; and

introducing excess ceramide and phosphatidylinositol,
said ceramide or phosphatidylinositol carrying label for
identi?cation, and test compound to said container; and
subjecting said container and contents to ordinary condi
tions necessary for ceramide conversion to phosphoi
nositol ceramide; and
identifying those test compounds Which inhibit ceramide
conversion to phosphoinositol ceramide.
2. The method of claim 1, Wherein the IPC1 gene is

30

14. A method to determine the ability of a test compound

to inhibit IPC synthase, comprising:

recombinantly expressing the Saccharomyces IPC1 gene
in a plurality of cells transformed to express said gene,

said cells being in homogeneous culture and located in
a container useful for addition of liquids; and

introducing excess biotinylated ceramide, phosphatidyli
nositol and test compound to said container; and
subjecting said container and contents to ordinary condi
tions necessary for ceramide conversion; and
conjugating said biotinylated ceramide to labeled

over-expressed.
3. The method of claim 1, Wherein the cells are chosen
from the group consisting of: E. coli; S. cerevisiae and S.

pombe.
4. A method of claim 1, Wherein the labeled starting
substrate is a C2—C12 ceramide.

5. A method of claim 4, Wherein the C2—C12 ceramide is
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NBD-CG-ceramide.
6. A method of claim 4, Wherein the C2—C12 ceramide is
BODIPY-CS-ceramide.
7. A method of claim 4, Wherein the C2—C12 ceramide is

N-hexanoyl-sphingosine.
8. A method of claim 4, Wherein the C2—C12 ceramide is
labeled With ?uorescent material.
9. A method of claim 4, Wherein the C2—C12 ceramide is
labeled With a radioactive material.

10. Amethod of claim 9, Wherein the radioactive material
is chosen from the group consisting of: 3H and 14C.

derivatiZed solid substrate; and
identifying those test compounds Which inhibit ceramide
conversion to phosphoinositol ceramide.
12. A method of claim 11, Wherein the solid substrate is
a plurality of scintillation proximity assay (SPA) beads.
13. A method of claim 11, Wherein the phosphatidylinosi
tol is labeled With label selected from the group consisting
of tritium and 32F.
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streptavidin-derivatiZed solid substrate capable of ?lter
separation; and
?ltering to isolate the labeled streptavidin-derivatiZed
solid substrate; and
identifying those test compounds Which inhibit ceramide
conversion to phosphoinositol ceramide.
15. A method of claim 11, Wherein the solid substrate is
a plurality of SPA beads.
16. Amethod of claim 14, Wherein the phosphatidylinosi
tol is labeled With label selected from the group consisting
of tritium and 32F.
17. A method to determine the ability of a test compound

to inhibit IPC synthase, comprising:
introducing into a container that contains a plurality of
untransformed cells that express IPC synthase, excess

11. A method to determine the ability of a test compound

to inhibit IPC synthase, comprising:

recombinantly expressing the Saccharomyces IPC1 gene

biotinylated ceramide, labeled phosphatidylinositol,

in a plurality of cells transformed to express said gene,

and test compound; and
subjecting said container and contents to ordinary condi
tions necessary for ceramide conversion to phosphoi
nositol ceramide; and
identifying those test compounds Which inhibit ceramide
conversion to phosphoinositol ceramide.

said cells being in homogeneous culture and located in
a container useful for addition of liquids; and

introducing excess biotinylated ceramide, labeled phos
phatidylinositol and test compound to said container;
and
subjecting said container and contents to ordinary condi
tions necessary for ceramide conversion; and
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